Core Insights - AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of 3 cents for the fourth quarter of fiscal 2025, which is an improvement from a loss of 6 cents in the same quarter last year and better than the Zacks Consensus Estimate of a loss of 13 cents [1][2][9] Financial Performance - The pro forma adjusted loss per share for the fourth quarter of fiscal 2025 was also 3 cents, compared to 5 cents in the year-ago quarter [2][3] - The GAAP loss per share was 15 cents, an improvement from 33 cents in the prior year [2][3] - Full-year fiscal 2025 adjusted loss per share was 15 cents, better than the 38 cents reported in fiscal 2024 and the Zacks Consensus Estimate of a loss of 29 cents [3] - Total revenues for the fourth quarter reached $80.2 million, reflecting a year-over-year increase of 12.9% and exceeding the Zacks Consensus Estimate by 7.5% [4][9] - Full-year fiscal 2025 revenues were $292.5 million, a decline of 3.8% from the previous year but still above the Zacks Consensus Estimate by 1.9% [5][6] Revenue Breakdown - U.S. net revenues for the fourth quarter were $67.5 million, up 11.1% year over year [7] - International revenues were $12.7 million, representing a 23.8% increase from the prior year [8] Segment Analysis - Med Tech revenues in the fourth quarter were $35.8 million, a 22% increase year over year [10][11] - Med Device revenues totaled $44.4 million, up 6.5% from the year-ago period [13] Margin and Expense Analysis - Pro forma gross profit increased by 9.4% to $42.2 million, but the gross margin contracted by 161 basis points to 52.7% [14] - Sales and marketing expenses rose by 7.6% to $26.4 million, while research and development expenses decreased by 1.9% to $6.6 million [15] Cash Position - AngioDynamics ended fiscal 2025 with cash and cash equivalents of $55.9 million, down from $76.1 million at the end of fiscal 2024 [17] - The company reported no debt on its balance sheet and a cumulative net cash used in operating activities of $10.1 million, compared to $28.2 million a year ago [17] Future Guidance - For fiscal 2026, AngioDynamics expects net sales to be between $305 million and $310 million, indicating growth of 4-6% from fiscal 2025 [18] - The company anticipates Med Tech revenue growth of 12-15%, while Med Device revenue growth is projected to be flat [18] - The adjusted loss per share is expected to range between 35 cents and 25 cents, with the Zacks Consensus Estimate at a loss of 24 cents per share [19] Market Developments - AngioDynamics received a CPT Category I Code for Irreversible Electroporation (IRE) for treating pancreatic lesions, effective January 1, 2027, which expands the reimbursement pathway for NanoKnife [22]

Core Viewpoint - AngioDynamics reported stronger-than-expected Q4 2025 sales and earnings, but the overall market reaction was negative due to ongoing losses and cautious guidance for the upcoming fiscal year [1][2][4]. Financial Performance - Q4 sales increased by 13% year-over-year, reaching $80.2 million, while gross profit margins declined by 160 basis points to 52.7% [4]. - Adjusted loss per share was $0.03, better than the forecasted loss of $0.12, and GAAP loss per share improved from $0.33 a year ago to $0.15 [4][5]. - For the full fiscal year 2025, AngioDynamics reported a loss of $0.83 per share under GAAP, with sales growth of only 8.1% [5]. Future Guidance - The company expects fiscal 2026 sales to be between $305 million and $310 million, which exceeds Wall Street forecasts [6]. - However, management warned of expected losses ranging from $0.25 to $0.35 per share, adjusted for one-time items, which is worse than the $0.23 per-share loss anticipated by analysts [6][7].

Core Insights - AngioDynamics Inc. reported a fourth-quarter 2025 adjusted loss of 3 cents per share, outperforming the consensus loss of 12 cents per share [1] - The company achieved sales of $80.2 million, reflecting a year-over-year increase of 12.7%, surpassing the consensus estimate of $74.26 million [1] - CEO Jim Clemmer stated that the company is "profitable" and its portfolio addresses approximately $10 billion in annual global market opportunities, up from $3 billion in 2021 [1] Financial Guidance - For fiscal year 2026, AngioDynamics expects net sales between $305 million and $310 million, slightly above the consensus of $304.9 million [2] - The company anticipates an adjusted loss between 35 and 25 cents per share, compared to the consensus loss of 23 cents per share [2] Tariff Impact and Financial Metrics - The company expects a $4 million to $6 million impact from tariffs for the full fiscal year 2026 [3] - The gross margin was reported at 52.7%, down 161 basis points from the fourth quarter of fiscal 2024; without the $1.6 million tariff impact, the gross margin would have been 54.7% [4] - Adjusted EBITDA for the quarter was $3.4 million, an increase from $1.5 million a year ago [4] Sales Performance - Med Tech net sales reached $35.8 million, a 22% increase from $29.3 million in the prior-year period, driven by Auryon sales of $15.6 million, which increased 19.7% [4] - Mechanical Thrombectomy revenue, including AngioVac and AlphaVac, was $11.3 million, marking a 44.7% increase [4] - Med Device net sales were $44.4 million, representing a 6.2% increase from $41.8 million in the prior-year period [4]

Core Insights - AngioDynamics reported a strong performance in Q4 FY2025, with total revenue of $80.2 million, reflecting a year-over-year increase of 12.7% driven by growth in both MedTech and med device segments [4][25][45] - The company emphasized the transformational impact of regulatory approvals and market expansion on future revenue potential, despite facing tariff-related headwinds [12][50][63] Financial Performance - Total revenue for FY2025 reached $292.7 million, up 8.1% from the previous year, with MedTech segment revenue growing 19.5% to $126.7 million [9][57] - Adjusted EBITDA for Q4 FY2025 was $3.4 million, an improvement from $1.5 million in Q4 FY2024, indicating margin improvement despite tariff impacts [8][54] - Gross margin for Q4 FY2025 was 52.7%, negatively impacted by tariffs, which reduced margins by 204 basis points [7][51] Segment Performance - MedTech revenue in Q4 FY2025 was $35.8 million, a 22% increase, while med device revenue was $44.4 million, up 6.2% [4][45] - The Auryon platform generated $15.6 million in revenue, growing 19.7% year-over-year, and has shown consistent double-digit growth since its launch [5][45][57] - Mechanical thrombectomy revenue, including AngioVac and AlphaVac, increased by 44.7% year-over-year, with AlphaVac revenue growing 60.8% [6][46][57] Guidance and Future Outlook - For FY2026, the company expects net sales between $305 million and $310 million, representing 4%-6% growth, with MedTech sales projected to increase by 12%-15% [10][60] - The company anticipates $15 million in annualized savings by FY2027 through manufacturing transitions, which will enhance operational efficiency [10][42] - Regulatory milestones, including a CPT Category I code for NanoKnife, are expected to drive growth and reimbursement access starting January 2026 [11][37][72] Strategic Initiatives - The company is focused on driving adoption and market share gains across its MedTech platforms while maintaining operational discipline [63][64] - Continued investments in clinical trials and evidence generation are planned to support product adoption and market penetration [11][29][38] - Management has indicated no plans for major acquisitions or divestitures in the near term, focusing instead on executing their current strategy [12][16]

Financial Data and Key Metrics Changes - Total revenue for the fourth quarter was $80.2 million, representing a year-over-year growth of over 12% [5][23] - MedTech revenue was $35.8 million, a 22% increase, while Med Device revenue was $44.4 million, an increase of 6.2% [23] - For the full fiscal year, total revenue increased by 8.1% to $292.7 million, primarily driven by growth in the MedTech segment [34][35] - Gross margin for the fourth quarter was 52.7%, with MedTech gross margin at 59% and Med Device gross margin at 47.6% [30][36] Business Line Data and Key Metrics Changes - AURYON platform generated $15.6 million in revenue, growing 19.7% year-over-year [23] - Mechanical thrombectomy revenue, including AngioVac and AlphaVac, increased by 44.7% year-over-year, with AngioVac revenue at $8.2 million (39.5% increase) and AlphaVac revenue at $3.1 million (60.8% increase) [24] - NanoKnife revenue totaled $7.2 million, a decrease of 2.5%, attributed to lower capital sales, while disposable sales grew by 5.5% [25] Market Data and Key Metrics Changes - Hospital customers represented approximately 36% of total AURYON revenue, up from 28% at the beginning of fiscal 2025 [7] - In Europe, over $1 million in revenue was generated from AURYON, indicating successful market entry following CE Mark approval [8] Company Strategy and Development Direction - The company is focused on a long-term strategic transformation to simplify its business and enter high-growth, high-margin MedTech markets [5][20] - Continued investment in R&D is planned, targeting approximately 10% of sales to support long-term growth in the MedTech segment [31] - The company aims to drive adoption and market share gains across its MedTech platforms while maintaining operational discipline [41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate tariff impacts and maintain profitability, expecting to be cash flow positive in fiscal 2026 [20][39] - The company anticipates net sales for fiscal 2026 to be in the range of $305 million to $310 million, representing growth of 46% over fiscal 2025 [38] Other Important Information - The company achieved significant regulatory approvals and reimbursement wins, which are expected to drive future growth [5][15] - The company incurred $1.6 million in tariff expenses during the fourth quarter, impacting gross margins [28] Q&A Session Summary Question: Details on the blood return product for the VTE business - Management confirmed that the blood return product is designed as an ancillary add-on and is undergoing the 510(k) regulatory process, with confidence in its market potential [46][50] Question: Expectations for NanoKnife growth with upcoming reimbursement - Management indicated that reimbursement starting in January 2026 is expected to drive growth, although immediate acceleration may not be seen [52][56] Question: Major product growth expectations for FY 2026 - Management expects AURYON to grow in the mid-teens, while mechanical thrombectomy products are anticipated to show the strongest growth [60][63] Question: Impact of tariffs on gross margin and outsourcing benefits - Management acknowledged the complexity of tariff impacts and indicated that benefits from the manufacturing transfer plan will be seen in FY 2026 [64][66] Question: Plans for acquiring new MedTech products or divesting existing ones - Management expressed satisfaction with the current portfolio and indicated no immediate plans for acquisitions or divestitures, focusing instead on maximizing existing assets [70][74]

Financial Performance - AngioDynamics' total Med Device revenue grew by 62% pro forma in Q4 2025[5,9] - AngioDynamics' total Med Tech revenue grew by 220% pro forma in Q4 2025[5,9] - AngioDynamics reported pro forma Adjusted EBITDA of $34 million in Q4 2025, a $19 million improvement from Q4 FY24[5] - AngioDynamics ended the quarter with $559 million in cash and cash equivalents, up from $448 million at Feb 28, 2025[5] - AngioDynamics' total Med Tech revenue grew by 195% pro forma for FY 2025[12] - AngioDynamics' total Med Device revenue grew by 08% pro forma for FY 2025[12] Product Line Performance - Auryon sales reached $156 million in Q4 2025, a 197% year-over-year growth[16] - Total Mechanical Thrombectomy sales were $113 million in Q4 2025, a 447% year-over-year growth[5,20] - NanoKnife disposables sales grew by 55% in Q4 2025, while total NanoKnife sales decreased by 25%[5,25] Future Outlook - AngioDynamics projects full-year net sales between $305 million and $310 million for Fiscal Year 2026[27]

[Financial Performance Overview](index=1&type=section&id=Financial%20Performance%20Overview) [Q4 Fiscal Year 2025 Performance](index=1&type=section&id=Q4%20Fiscal%20Year%202025%20Performance) The company reported strong Q4 FY2025 results with **12.7% pro forma net sales growth**, driven by a **22.0% increase in the Med Tech franchise**, achieving positive pro forma adjusted EBITDA of **$3.4 million** and generating significant free cash flow of **$16.2 million**, demonstrating successful strategic transformation Q4 Fiscal Year 2025 Financial Highlights (Pro Forma) | Metric | Value | YoY Growth | | :--- | :--- | :--- | | Pro Forma Net Sales | $80.2 million | 12.7% | | Med Tech Net Sales | $35.8 million | 22.0% | | Med Device Net Sales | $44.4 million | 6.2% | | Pro Forma Adjusted EBITDA | $3.4 million | - | | Pro Forma Adjusted EPS | $(0.03) | - | - The company generated **$16.2 million** in free cash flow during the fourth quarter, attributed to strong revenue growth and operational efficiency initiatives[1](index=1&type=chunk) - GAAP gross margin for the quarter was **52.7%**, negatively impacted by **$1.6 million** (**204 basis points**) due to tariffs[2](index=2&type=chunk) [Full Fiscal Year 2025 Performance](index=2&type=section&id=Full%20Fiscal%20Year%202025%20Performance) For the full fiscal year 2025, AngioDynamics achieved **8.1% pro forma net sales growth**, with the Med Tech segment growing **19.5%**, reporting positive pro forma adjusted EBITDA of **$7.6 million** and ending the year with a strong cash position of **$55.9 million**, ahead of expectations Full Fiscal Year 2025 Financial Highlights (Pro Forma) | Metric | Value | YoY Growth | | :--- | :--- | :--- | | Pro Forma Net Sales | $292.7 million | 8.1% | | Med Tech Net Sales | $126.7 million | 19.5% | | Med Device Net Sales | $166.0 million | 0.8% | | Pro Forma Adjusted EBITDA | $7.6 million | - | | Pro Forma Adjusted EPS | $(0.25) | - | - The company ended fiscal 2025 with **$55.9 million** in cash and cash equivalents, which was ahead of expectations[5](index=5&type=chunk) - Adjusted EBITDA for the year was **$13.1 million**, including a **$5.5 million** milestone earnout payment received from Spectrum Vascular in Q3 FY25[5](index=5&type=chunk) [Business Highlights and Strategic Developments](index=2&type=section&id=Business%20Highlights%20and%20Strategic%20Developments) The company highlighted significant strategic progress in FY2025, including achieving key regulatory milestones for NanoKnife and AlphaVac, expanding into European markets with Auryon, and securing a new credit facility, emphasizing its transformation into a growth-oriented MedTech firm addressing a larger market opportunity, now estimated at **over $10 billion** - The company has repositioned itself to address **over $10 billion** in annual global market opportunities, a significant increase from **$3 billion** in 2021[7](index=7&type=chunk) - Key achievements include NanoKnife's FDA prostate indication, a CPT Category I Code for Irreversible Electroporation (IRE), AlphaVac's successful commercial launch, and Auryon's European expansion[5](index=5&type=chunk)[6](index=6&type=chunk) - A new revolving credit facility of up to **$25.0 million** was established to enhance financial flexibility and support working capital at a low cost without dilution[5](index=5&type=chunk) [Detailed Financial Results](index=3&type=section&id=Detailed%20Financial%20Results) [Fourth Quarter Fiscal 2025 Financial Results](index=3&type=section&id=Fourth%20Quarter%20Fiscal%202025%20Financial%20Results) Q4 pro forma net sales reached **$80.2 million**, up **12.7% YoY**, with Med Tech sales growing **22.0%** to **$35.8 million** and Med Device sales up **6.2%** to **$44.4 million**, with strong growth in both U.S. (**11.0%**) and International (**22.8%**) markets, while GAAP gross margin was **52.7%**, impacted by tariffs, and pro forma adjusted EBITDA was **$3.4 million**, more than doubling from **$1.5 million** in the prior-year quarter Q4 FY2025 Sales Performance (Pro Forma) | Category | Net Sales (millions) | YoY Growth | | :--- | :--- | :--- | | **Total Net Sales** | **$80.2** | **12.7%** | | Med Tech | $35.8 | 22.0% | | Med Device | $44.4 | 6.2% | | U.S. Sales | $67.5 | 11.0% | | International Sales | $12.7 | 22.8% | Q4 FY2025 Med Tech Product Sales Growth | Product Line | Sales (millions) | YoY Growth | | :--- | :--- | :--- | | Auryon | $15.6 | 19.7% | | Mechanical Thrombectomy | $11.3 | 44.7% | | NanoKnife Disposables | $5.7 | 5.5% | Q4 FY2025 Profitability | Metric | Value | Note | | :--- | :--- | :--- | | GAAP Gross Margin | 52.7% | Would be 54.7% absent tariff impact | | GAAP Net Loss | $(6.1) million | - | | Adjusted Net Loss | $(1.0) million | - | | Adjusted EBITDA | $3.4 million | Compared to $1.5M in Q4 FY24 | - Tariffs had a significant impact on Q4 gross margin, creating a **$1.6 million** cost of goods sold headwind, equivalent to **204 basis points**[17](index=17&type=chunk) [Full-Year Fiscal 2025 Financial Results](index=4&type=section&id=Full-Year%20Fiscal%202025%20Financial%20Results) For the full fiscal year, pro forma net sales grew **8.1%** to **$292.7 million**, led by a **19.5%** increase in Med Tech sales to **$126.7 million**, with GAAP gross margin at **53.9%**, slightly impacted by tariffs, and pro forma adjusted EBITDA at **$7.6 million**, a significant improvement from a loss of **$3.2 million** in the prior year, reflecting successful strategic shifts and operational efficiencies Full Year FY2025 Sales Performance (Pro Forma) | Category | Net Sales (millions) | YoY Growth | | :--- | :--- | :--- | | **Total Net Sales** | **$292.7** | **8.1%** | | Med Tech | $126.7 | 19.5% | | Med Device | $166.0 | 0.8% | Full Year FY2025 Profitability | Metric | FY2025 Value | FY2024 Value | | :--- | :--- | :--- | | GAAP Gross Margin | 53.9% | 53.8% | | GAAP Net Loss | $(34.0) million | $(184.3) million | | Adjusted Net Loss | $(10.2) million | $(18.2) million | | Pro Forma Adjusted EBITDA | $7.6 million | $(3.2) million | - The company's cash and cash equivalents stood at **$55.9 million** as of May 31, 2025, which was ahead of expectations despite a **$5.0 million** milestone payment for the Auryon acquisition[23](index=23&type=chunk) - For the full fiscal year, tariffs had a **$1.6 million** impact on cost of goods sold, representing a **56 basis point** headwind to gross margin[24](index=24&type=chunk) [Fiscal Year 2026 Outlook](index=6&type=section&id=Fiscal%20Year%202026%20Outlook) [Financial Guidance](index=6&type=section&id=Financial%20Guidance) AngioDynamics provided its financial guidance for fiscal year 2026, projecting net sales between **$305 million** and **$310 million**, anticipating continued strong growth in Med Tech (**12-15%**), flat performance in Med Device, and expecting to generate positive free cash flow for the full year, with profitability guidance, including an adjusted EPS range of **($0.35)** to **($0.25)**, incorporating expected tariff impacts Fiscal Year 2026 Guidance (as of July 15, 2025) | Guidance Metric | Current Guidance | Guidance Absent Tariffs | | :--- | :--- | :--- | | Net Sales | $305 - $310 million | - | | Med Tech Net Sales Growth | 12% - 15% | - | | Med Device Net Sales Growth | Flat | - | | Gross Margin | 53.5% - 55.5% | 55.0% - 56.0% | | Pro Forma Adjusted EBITDA | $3.0 - $8.0 million | $7.5M - $10.5M | | Adjusted EPS | ($0.35) - ($0.25) | ($0.30) – ($0.25) | | Free Cash Flow | Positive for Full Year | Up to +$5M | [Tariff-Related Assumptions](index=6&type=section&id=Tariff-Related%20Assumptions) The company's FY2026 guidance incorporates an expected negative impact from tariffs ranging from **$4.0 million** to **$6.0 million**, with guidance ranges for gross margin, pro forma adjusted EBITDA, and adjusted EPS reflecting this uncertainty, where the low end assumes the highest tariff impact and the high end assumes the lowest - For fiscal year 2026, the company anticipates a **$4.0 to $6.0 million** negative impact from tariffs[26](index=26&type=chunk) - The provided guidance ranges for profitability metrics are structured so that the low end assumes the highest tariff impact, while the high end assumes the lowest[26](index=26&type=chunk) [Financial Statements and Reconciliations](index=8&type=section&id=Financial%20Statements%20and%20Reconciliations) [Consolidated Income Statements](index=8&type=section&id=Consolidated%20Income%20Statements) The consolidated income statements provide a detailed breakdown of revenues, costs, and expenses for Q4 and full fiscal year 2025, compared to the prior year, presented on both US GAAP (Actual) and pro forma bases, with adjustments to exclude operating results from divested and discontinued businesses for a clearer view of ongoing operations - The income statements for both the three-month and twelve-month periods ending May 31, 2025, are presented with columns for Actual (US GAAP), Pro Forma Adjustments, and the resulting Pro Forma figures[33](index=33&type=chunk)[37](index=37&type=chunk) - Pro forma adjustments eliminate revenues and expenses from divested businesses (Dialysis, BioSentry, PICCs, Midlines) and discontinued products (RadioFrequency Ablation, Syntrax) to facilitate like-for-like comparison[34](index=34&type=chunk)[38](index=38&type=chunk) [GAAP to Non-GAAP Reconciliations](index=10&type=section&id=GAAP%20to%20Non-GAAP%20Reconciliations) This section provides detailed reconciliations of GAAP financial measures to non-GAAP measures, including Adjusted Net Loss, Adjusted Diluted Loss Per Share, and Adjusted EBITDA, for both actual and pro forma results, adjusting for items like amortization of intangibles, restructuring costs, and other non-recurring items to offer management's view of underlying operational performance - Reconciliations are provided to bridge GAAP Net Loss to non-GAAP Adjusted Net Loss and Adjusted EBITDA[39](index=39&type=chunk)[42](index=42&type=chunk) - Key adjustments include amortization of intangibles, acquisition/restructuring costs, stock-based compensation, and changes in fair value of contingent consideration[39](index=39&type=chunk)[42](index=42&type=chunk)[44](index=44&type=chunk) - A detailed breakdown of 'Acquisition, restructuring and other items' is provided, showing costs related to legal matters, plant closures, and transition service agreements[50](index=50&type=chunk) [Net Sales and Gross Margin Analysis](index=15&type=section&id=Net%20Sales%20and%20Gross%20Margin%20Analysis) The company provides a detailed breakdown of net sales and gross margin by its two main product categories, Med Tech and Med Device, and by geography (United States and International), with Q4 FY2025 Med Tech pro forma sales growing **22.0%** with a **59.0%** gross margin, and Med Device sales growing **6.2%** with a **47.6%** gross margin Q4 FY2025 Pro Forma Sales & Gross Margin by Category | Category | Net Sales (millions) | YoY Growth | Gross Margin % | | :--- | :--- | :--- | :--- | | Med Tech | $35.8 | 22.0% | 59.0% | | Med Device | $44.4 | 6.2% | 47.6% | Full Year FY2025 Pro Forma Sales & Gross Margin by Category | Category | Net Sales (millions) | YoY Growth | Gross Margin % | | :--- | :--- | :--- | :--- | | Med Tech | $126.7 | 19.5% | 62.0% | | Med Device | $166.0 | 0.8% | 47.7% | [Consolidated Balance Sheet](index=17&type=section&id=Consolidated%20Balance%20Sheet) The consolidated balance sheet as of May 31, 2025, shows total assets of **$280.1 million** and total liabilities of **$97.2 million**, with the company ending the fiscal year with **$55.9 million** in cash and cash equivalents, a decrease from **$76.1 million** in the prior year, reflecting operational investments, debt management, and milestone payments Key Balance Sheet Items (in thousands) | Account | May 31, 2025 | May 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $55,893 | $76,056 | | Total current assets | $168,324 | $193,253 | | Total assets | $280,144 | $317,671 | | Total current liabilities | $76,197 | $91,155 | | Total liabilities | $97,174 | $112,085 | | Total stockholders' equity | $182,970 | $205,586 | [Consolidated Statement of Cash Flows](index=18&type=section&id=Consolidated%20Statement%20of%20Cash%20Flows) For the twelve months ended May 31, 2025, the company reported a net cash outflow from operating activities of **$10.1 million** and a net cash outflow from investing activities of **$10.2 million**, with the cash position impacted by operating losses, a **$5.0 million** contingent consideration payment, and capital expenditures, resulting in a net decrease in cash of **$20.2 million** for the year Twelve Months Ended May 31, 2025 Cash Flow Summary (in thousands) | Cash Flow Category | Value | | :--- | :--- | | Net cash used in operating activities | $(10,128) | | Net cash used in investing activities | $(10,178) | | Net cash used in financing activities | $(255) | | **Net decrease in cash and cash equivalents** | **$(20,163)** | - In Q4 2025, the company generated positive net cash from operating activities of **$18.8 million**, a significant improvement from **$5.0 million** in the prior-year quarter[72](index=72&type=chunk)

Core Insights - The Medical Instruments industry is experiencing significant advancements due to artificial intelligence (AI) and predictive analytics, which are driving innovation in diagnostics, patient monitoring, and personalized treatment [2][4] - The global AI in healthcare market is projected to grow at a CAGR of 38.5% from 2024 to 2030, despite facing challenges such as geopolitical tensions and supply chain issues [4][8] - The industry is currently underperforming compared to the S&P 500 but has shown resilience against sector declines [17] Industry Overview - The Zacks Medical - Instruments industry is highly fragmented, involving extensive research and development across various therapeutic areas, regulated by the FDA [5] - Recent trends include the integration of AI in diagnostics, the rise of telemedicine, robotic-assisted surgeries, and advancements in 3D printing and gene editing [6][9] - The ongoing merger and acquisition trend is notable, with 305 M&A transactions in 2024 totaling over $63.1 billion, indicating a competitive landscape [10][11] Company Highlights Integer Holdings - Integer Holdings focuses on portfolio optimization and has divested its Non-Medical business to support long-term growth [20] - The consensus estimate for 2025 sales is $1.87 billion, reflecting a 7.7% increase from 2024, with EPS expected to rise by 19.4% to $6.33 [21] AngioDynamics - AngioDynamics is focusing on cancer treatment markets and has a strong product pipeline, with sales for fiscal 2026 estimated at $305 million, a 6.3% increase from fiscal 2025 [22][23] Penumbra - Penumbra is experiencing consistent revenue growth driven by strong patient outcomes and growth in its vascular and neuro businesses [24] - The consensus estimate for Penumbra's 2025 sales is $1.35 billion, indicating a 13.4% rise from 2024, with EPS expected to improve by 67.6% to $3.72 [25]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: AngioDynamics (ANGO) - AngioDynamics currently holds a Momentum Style Score of B, indicating potential for strong performance based on price changes and earnings estimate revisions [3] - The company has a Zacks Rank of 1 (Strong Buy), suggesting it is expected to outperform the market [4] Performance Metrics - Over the past week, ANGO shares increased by 7.94%, significantly outperforming the Zacks Medical - Instruments industry, which rose by only 0.37% [6] - In a longer timeframe, ANGO's shares have risen by 20.07% over the past quarter and 71.09% over the last year, while the S&P 500 only increased by 2.37% and 14.4%, respectively [7] Trading Volume - The average 20-day trading volume for ANGO is 535,625 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, two earnings estimates for ANGO have been revised upwards, leading to an increase in the consensus estimate from -$0.36 to -$0.29 [10] - For the next fiscal year, two estimates have also moved upwards with no downward revisions, indicating positive sentiment [10] Conclusion - Given the strong performance metrics and positive earnings outlook, ANGO is positioned as a 1 (Strong Buy) stock with a Momentum Score of B, making it a compelling investment opportunity [12]

Group 1 - AngioDynamics (ANGO) has shown strong year-to-date performance, returning 9.2% compared to the Medical sector's average return of -5.6% [4] - The Zacks Consensus Estimate for AngioDynamics' full-year earnings has increased by 22.5% over the past 90 days, indicating improved analyst sentiment [4] - AngioDynamics holds a Zacks Rank of 1 (Strong Buy), suggesting it has characteristics to outperform the market in the near term [3] Group 2 - AngioDynamics is part of the Medical - Instruments industry, which consists of 85 companies and currently ranks 90 in the Zacks Industry Rank [6] - The Medical - Instruments industry has an average year-to-date loss of 8.9%, highlighting AngioDynamics' relative outperformance [6] - Chugai Pharmaceutical Co., Ltd. Unsponsored ADR has also outperformed its sector with an 18.8% return this year and a Zacks Rank of 2 (Buy) [5][7]